First trimester contingent testing with either nuchal translucency or cell‐free DNA. Cost efficiency and the role of ultrasound dating
Authors:
- 17 February 2015
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 94 (4) , 368-375
Abstract
Objective: To evaluate the performance and cost efficacy of different first‐trimester contingent screening strategies based on an initial analysis of biochemical markers.Design: Retrospective study.Setting: Swedish National Quality Register for prenatal diagnosis.Population: 35 780 women with singleton pregnancies.Methods: Serum values from first trimester biochemistry were re‐analyzed in a contingent approach. For risks between 1:40 and 1:1000, risk estimates from nuchal translucency measurements were added and outcomes were compared using either a final cut‐off risk of 1:200 to proceed with invasive testing or offering non‐invasive prenatal testing. In a subgroup of 12 836 women with regular menstrual cycles the same analyses were performed using data on the last menstrual period for determining gestational age. The costs of detecting one case of aneuploidy were compared.Main outcome measures: Comparison of screening strategies.Results: The detection rate was the same (87%) in the contingent group as in complete combined screening, with only 41% requiring a nuchal translucency scan. As an alternative, offering non‐invasive prenatal testing to the intermediate risk group would result in a detection rate of 98%, but the cost to detect one case of trisomy 21 would be 83% higher than the cost associated with traditional combined screening.Conclusions: First trimester examination using a contingent approach will achieve similar results compared with full combined screening. Non‐invasive prenatal testing will not be cost‐effective when a high proportion of pregnancies need further testing.Keywords
This publication has 28 references indexed in Scilit:
- Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA SequencingObstetrics & Gynecology, 2012
- DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative studyGenetics in Medicine, 2012
- Implications of a first trimester Down syndrome screening program on timing of malformation detectionActa Obstetricia et Gynecologica Scandinavica, 2011
- Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity studyBMJ, 2011
- Prospective validation of first‐trimester combined screening for trisomy 21Ultrasound in Obstetrics & Gynecology, 2009
- First‐trimester contingent screening for Down syndrome can reduce the number of nuchal translucency measurements requiredPrenatal Diagnosis, 2008
- Nuchal Translucency Measurements for First-Trimester Screening: The ‘Price’ of InaccuracyFetal Diagnosis and Therapy, 2007
- Detection of malformations in chromosomally normal fetuses by routine ultrasound at 12 or 18 weeks of gestation—a randomised controlled trial in 39 572 pregnanciesBJOG: An International Journal of Obstetrics & Gynaecology, 2006
- An increase in cost‐effectiveness of first trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testingPrenatal Diagnosis, 2002
- Screening for trisomy 13 by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000